Novel Oral Anticoagulants in Cardiovascular Practice


  • Syed Haseeb Raza Chaudhry Pervaiz Elahi Institute of Cardiology, Multan, Pakistan
  • Han Naung Tun University of Vermont, Burlington City, Vermont State, USA
  • F. Aaysha Cader Ibrahim Cardiac Hospital & Research Institute, Dhaka, Bangladesh
  • Jolanda Sabatino University of Padua, Italy
  • Madiha Fatima National Institute of Cardiovascular Diseases, Karachi, Pakistan



In the recent era of medicine, Novel Oral Anticoagulants (Apixaban, Dabigatran, Edoxaban, and Rivaroxaban) have become the preferred drugs for long-term anticoagulation therapy in the majority of cardiovascular conditions, along with non-cardiac co-morbid conditions with few necessary exceptions. This preference is based on their easy availability, therapeutic efficacy, all-cost effectiveness, safety profile, and more convenient usage for both patients and clinicians.

Novel Oral Anticoagulants (NOACs) have different pharmacokinetics and pharmacodynamics than oral vitamin K antagonists. This article highlights the basic pharmacology, common complications, available antidotes, and the utility of NOACs in different common cardiovascular diseases requiring long-term oral anticoagulation, including stroke prevention in valvular and non-valvular atrial fibrillation, coronary artery disease, myocardial infarction, left ventricular thrombus and cerebrovascular attacks.

NOACs are still underutilized in cardiovascular practice because the concomitant co-morbid conditions hinder a clinician from prescribing these drugs confidently. This manuscript will provide a brief critical overview to help clinicians prescribe NOACs more conveniently.


Download data is not yet available.




How to Cite

Raza SH, Tun HN, Cader FA, Sabatino J, Fatima M. Novel Oral Anticoagulants in Cardiovascular Practice. Pak Heart J [Internet]. 2023Dec.31 [cited 2024Jun.16];56(4):250-5. Available from: